Abstract
No series have reported the results of the use of the therapeutic anti-CD20 monoclonal antibody (Rituximab) in the setting of adult refractory/relapsed B-ALL. We report here the outcomes of such nine patients treated at two french institutions by a combination of Rituximab+chemotherapy. We showed that four patients could achieve complete response while four other patients were documented with blast clearance superior to 50% from the baseline in bone marrow. We conclude that our results suggested some efficacy for the use of Rituximab in combination with chemotherapy in the setting of refractory/relapsed adult B-ALL. Larger series within prospective trials are needed to confirm these results.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antigens, CD20 / metabolism*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Dexamethasone / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Resistance, Neoplasm / drug effects*
-
Female
-
Humans
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Neoplasm Recurrence, Local / genetics
-
Neoplasm Recurrence, Local / metabolism
-
Neoplasm Staging
-
Neoplasm, Residual / drug therapy
-
Neoplasm, Residual / genetics
-
Neoplasm, Residual / metabolism
-
Pilot Projects
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
-
Prognosis
-
Remission Induction
-
Risk Factors
-
Rituximab
-
Salvage Therapy*
-
Survival Rate
-
Vincristine / administration & dosage
-
Young Adult
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Cytarabine
-
Rituximab
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Methotrexate